Pfizer Eliminates Roadblock To Remicade Biosimilar Launch
Executive Summary
October launch seems more certain after district court rules patent covering the antibody is invalid; litigation continues over cell culture media patent that expires in 2027.
You may also be interested in...
Can Janssen Revive Its Key Remicade Patent? Federal Circuit Hears Pitch
Oral arguments suggest Janssen may have difficulty getting reversal of district court and patent office rulings that its composition patent is invalid.
Can Janssen Revive Its Key Remicade Patent? Federal Circuit Hears Pitch
Oral arguments suggest Janssen may have difficulty getting reversal of district court and patent office rulings that its composition patent is invalid.
Biosimilar Litigation: Janssen Vs. Samsung Anticipates Supreme Court Decision
Hoping to hold off a biosimilar to Remicade, Janssen challenges Samsung's decision not to participate in patent dance as it claims infringement of three manufacturing patents.